7 Hrs
Source:
اقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
7 Hrsاقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
7 HrsReady to play
Ready to play
Novo Nordisk raised its full-year outlook, supported by sales of its weight-loss drug Wegovy. It now expects sales and profits to grow by as much as 2% at constant exchange rates, or decline by no more than 2%, compared with its previous forecast of a 6% drop. The company’s shares jumped as much as 6.6% in early trading, reaching their highest level in six months.
Notice: This Is an AI-Generated Summary
Comments (0)